PeptSense
Create account

Peptide research

Tesamorelin — compounding legality overview

Tesamorelin has an FDA-approved product (Egrifta). Compounding may hinge on approved-drug component rules and state interpretation — not on clinic marketing claims.

Approved-drug component path

Common names: Egrifta

PeptSense tracks Tesamorelin across federal 503A Bulks List chain steps, PCAC advisory context, and state board positions. Status is never inferred from forums or marketing sites — only published citations with effective dates.

Federal 503A snapshot (illustrative)

Latest published federal event for 503A compounding pharmacies. Sign in for your licensed states and facility type.

Under Review
Summary
Honest curation baseline (2026-08-01): Tesamorelin has an FDA-approved product (Egrifta). Component / copy analysis is fact-specific — under_review until a dedicated citation is curated. Not a legal determination.
Citation
FDA compounding hub
Effective
Aug. 1, 2026

Not a legal determination. Replace placeholder citations during curation.

Run a full lookup

Get federal + state lanes, chain steps, printable answer cards, and compliance documents for the states you license in.

Create account View pricing

Related research topics

  • tesamorelin compounding
  • tesamorelin 503A

← All peptides · Resources hub